FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

		00540
Vashington,	D.C.	20549

eck this box if no longer subject
Section 16. Form 4 or Form 5
gations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Troendle August J.</u>						2. Issuer Name and Ticker or Trading Symbol Medpace Holdings, Inc. [MEDP]										ationship k all app Direc	,	•	X 10% (Owner		
(Last) C/O ME	Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 02/16/2024									X	Office below	•	CEO	Other (specify below)				
5375 MEDPACE WAY					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) CINCINNATI OH 45227				X Form filed by One Reporting Person Form filed by More than One Reporting Person																		
(City)	(St	rate) (2	Zip)		Rule 10b5-1(c) Transaction Indication																	
					Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
Di Di			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			nd 5) Securities Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Cod	e V	,	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 02/16			02/16/202	24	4			S ⁽¹⁾			50,000	D	\$391.75	1.75(2)		5,539,947		Ι	By Medpace Investors, LLC ⁽³⁾			
Common Stock 02/2			02/20/202	24)		13,988	D	\$386.39	.39(4) 5,525,959		I		By Medpace Investors, LLC ⁽³⁾				
Common	Stock															800	5,643	D				
		Tal	ble I	l - Derivati (e.g., pu								posed of, convertil				Owne	d					
1. Title of Derivative Security (Instr. 3)	itle of 2. 3. Transaction 3A. Deemed Execution Date, urity or Exercise (Month/Day/Year) if any		4. Trans	ransaction of Derivative (A) or Dispose of (D) (Instr. 3, and 5)		lumbe ivative curities quired or posed D)	6. Date Expiration (Month/Date de la contraction (Month/Date de la contraction de la			rcisable and Date /Year)	7. Title and Amount of Securities Underlying Derivative Security (Inst: 3 and 4) Amour or Numbe of Title Shares		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)				

Explanation of Responses:

- 1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period.
- 2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$390.06 to \$394.95. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$385.00 to \$389.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

Remarks:

/s/ Stephen P. Ewald, Attorney-in-Fact for August J. 02/21/2024 **Troendle**

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.